- JP-listed companies
- Cash flow
(219A) Cash flow
Market cap
¥42.1B
P/E ratio
-19.3x
Heartseed develops regenerative heart muscle therapies using iPS cell-derived cardiac spheres to treat severe heart failure patients through medical institutions worldwide.
| 2022/10 | 2023/10 | 2024/10 | 2025/12 | |
| Depreciation & amortization | 0 | 8 | 42 | 53 |
| Cash from operations | -1,922 | -798 | -1,343 | 1,081 |
| Capital expenditures | - | -328 | -14 | -29 |
| Cash from investing | -1 | -426 | -67 | 73 |
| Cash from financing | -22 | 1,848 | 2,119 | 376 |